Monitor upcoming FDA and CE Mark decisions as key catalysts. The company's cash position of $22.3M supports operations through these milestones, but the widening net loss warrants attention on the burn rate in subsequent quarters.
Price Chart
Executive Summary
SS Innovations filed an updated October 2026 corporate presentation via 8-K (Item 7.01). The presentation highlights strong operational momentum: 1H'26 revenue of $25.0M (+66% YoY), 244 cumulative SSi Mantra system installations, and 14,503 total surgeries performed. The company is progressing toward EU CE Mark (anticipated Q4 2026) and US FDA clearance (anticipated Q1 2027). The filing is a routine investor update with no new material financial disclosures beyond previously reported figures.
Key Facts
- 1H'26 revenue of $25,041,075, up 66% from $15,120,915 in 1H'25
- 244 SSi Mantra systems installed as of September 28, 2026, up from 224 as of June 30, 2026
- 14,503 multi-specialty surgeries completed to date
- Gross margin improved to 49.6% in 1H'26 from 46.3% in 1H'25
- EU CE Mark anticipated Q4 2026; US FDA clearance anticipated Q1 2027
- Cash of $22.3M (incl. $8.6M restricted) as of June 30, 2026
- Insider ownership ~72% as of June 12, 2026
- Net loss of $6.2M in 1H'26 vs $5.9M in 1H'25
Financial Impact
1H'26 revenue $25.0M (+66% YoY); net loss $6.2M; cash $22.3M
Risk Factors
- Regulatory delays for EU CE Mark or US FDA clearance
- Continued net losses and cash burn
- Dependence on India market (~87% of 2025 revenue)
- High insider ownership (~72%) limits public float
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-106654 |
| Document: ea0307579-8k_ssinnova.htm | 0001213900-26-106654 |
| Document: 0001213900-26-106654-index-headers.html | 0001213900-26-106654 |
| Document: 0001213900-26-106654-index.html | 0001213900-26-106654 |
| Document: 0001213900-26-106654.txt | 0001213900-26-106654 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $2.37 | awaiting T+5 | — | $2.50 (+5.49%) |
Oct 26, 2026 1d ago | Press Release | $2.37 | awaiting T+5 | — | $2.50 (+5.49%) |
Oct 13, 2026 14d ago | 8-K | $2.55 $2.54 | ▼ −0.39% | ▲ +0.76% | $2.50 (−1.96%) |
Oct 13, 2026 14d ago | 8-K | $2.55 $2.54 | ▲ +0.39% | ▼ −0.76% | $2.50 (+1.96%) |
Oct 9, 2026 18d ago | 424B5 | $2.55 $2.45 | ▲ +3.92% | ▲ +2.43% | $2.50 (+1.96%) |
Oct 5, 2026 22d ago | 8-K | $2.77 $2.55 | ▼ −7.94% | ▼ −8.36% | $2.50 (−9.75%) |
Sep 10, 2026 6w ago | 8-K | $3.30 $3.26 | ▼ −1.21% | ▼ −0.71% | $2.50 (−24.24%) |
Aug 13, 2026 10w ago | 8-K | $3.83 $3.61 | ▼ −5.74% | ▼ −3.78% | $2.50 (−34.73%) |
Jul 17, 2026 14w ago | 8-K | $3.64 $3.57 | ▼ −1.92% | ▼ −1.24% | $2.50 (−31.32%) |
Jul 14, 2026 15w ago | 8-K | $3.67 $3.75 | ▲ +2.18% | ▲ +3.48% | $2.50 (−31.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers